IMP3 expression in human ovarian cancer is associated with improved survival

International Journal of Gynecological Pathology

Volumn 28, Issue 3, 2009, Pages 203-210

  Noske, Aurelia ^a   Faggad, Areeg ^a   Wirtz, Ralph ^b   Darb Esfahani, Silvia ^a   Sehouli, Jalid ^a   Sinn, Bruno ^a   Nielsen, Finn Cilius ^c   Weichert, Wilko ^a   Buckendahl, Ann Christin ^a   Röske, Annika ^a   Müller, Berit ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SIEMENS AG   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

IMP3; Ovarian cancer; Prognosis

Indexed keywords

BINDING PROTEIN; MESSENGER RNA; PROTEIN IP3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 69049105356     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318189a724     Document Type: Article

References (31)

1. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-1270 (Pubitemid 29046868)
2. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005;280:18517-18524 (Pubitemid 41389102)
3. Nielsen FC, Nielsen J, Kristensen MA, et al. Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH domains. J Cell Sci 2002;115:2087-2097 (Pubitemid 34746375)
4. Ross AF, Oleynikov Y, Kislauskis EH, et al. Characterization of a beta-actin mRNA zipcode-binding protein. Mol Cell Biol 1997;17:2158-2165 (Pubitemid 27133302)
5. Doyle GA, Betz NA, Leeds PF, et al. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 1998;26:5036-5044
6. Runge S, Nielsen FC, Nielsen J, et al. H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. J Biol Chem 2000;275:29562-29569 (Pubitemid 32043834)
7. Farina KL, Hüttelmaier S, Musunuru K, et al. Two ZBP1 KH domains facilitate β-actin mRNA localization, granule formation, and cytoskeletal attachment. JCB 2003;160:77-87. (Pubitemid 36091718)
8. Jønson L, Vikessa J, Krogh A, et al. Molecular composition of IMP1 ribonucleoprotein granules. Mol Cell Proteomics 2007;6:798-811. (Pubitemid 46831932)
9. Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 2005;97:87-96. (Pubitemid 40220715)
10. Hammer NA, Hansen TO, Byskov AG, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005;130:203-212
11. Müller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729-2733 (Pubitemid 27283112)
12. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Can 2003;88:887-894 (Pubitemid 36520876)
13. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-564 (Pubitemid 43923666)
14. INK4a expression. Mod Pathol 2007;20:242-247
15. Li C, Zota V, Woda BA, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol 2007;20:1263-1268 (Pubitemid 350126850)
16. Pryor JG, Bourne PA, Yang Q, et al. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 2008;21:431-437
17. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. Gynecol Oncol 1998;70:2-12.
18. Denkert C, Fürstenberg A, Daniel PT, et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the antiinflammatory drug NS398, but not by COX-2 specific RNA interference. Oncogene 2003;22:8653-8661 (Pubitemid 38010488)
19. Noske A, Kaszubiak A, Weichert W, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett 2007;246:190-200. (Pubitemid 44959391)
20. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995;218:499-507.
21. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006;25:1456-1468
22. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 2004;24:671-678
23. Yantiss RK, Wode BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Sur Pathol 2005;29:188-195
24. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3 a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008;32:304-315 (Pubitemid 351172146)
25. Mori H, Sakakibara S, Imai T, et al. Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res 2001;64:132-143 (Pubitemid 32260183)
26. Köbel M, Weidensdorfer D, Reinke C, et al. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene 2007;26:7584-7589 (Pubitemid 350207710)
27. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999;88:95-99 (Pubitemid 29467415)
28. Newell S, Ward A, Graham C. Discriminating translation of insulin-like growth factor-II (IGF-II) during mouse embryogenesis. Mol Reprod Dev 1994;39:249-258 (Pubitemid 24341290)
29. Murphy SK, Huang Z, Wen Y, et al. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006;4:283-292
30. Spentzos D, Cannistra SA, Grall F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer 2007;14:781-790 (Pubitemid 350074066)
31. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. PNAS 2005;102:7677-7682 (Pubitemid 40741030)